Summit Therapeutics is trading at $15.02, down 5.10%, with broad risk-off sentiment potentially contributing.
- The S&P 500 was down 1.11% and the Nasdaq 1.87% pre-market; a separate report also cited weaker U.S. futures and Asian markets.
- Summit’s proposed increase in authorized shares is in focus, but reporting does not establish it caused the decline.
- Clinical-trial collaboration news was announced October 21; no clear link to the move is established.